Introduction: Why pH Matters in Cancer

Over the past decade, the tumor microenvironment has emerged as a critical determinant of cancer progression and treatment response. While genetic mutations drive the initial transformation of normal cells into malignant ones, the local chemical and physical conditions surrounding a tumor—including oxygen tension, nutrient availability, and pH—profoundly influence how aggressively the disease behaves. Among these factors, pH stands out as a particularly powerful regulator. Unlike healthy tissues, which maintain a tightly controlled physiological pH around 7.4, solid tumors often exhibit a markedly acidic extracellular pH, frequently ranging from 6.5 to 6.9. This acidic microenvironment is not merely a byproduct of cancer metabolism; it actively shapes tumor evolution, facilitates invasion and metastasis, and creates significant barriers to effective therapy.

Understanding the relationship between pH and cancer is therefore not an academic curiosity—it has direct implications for diagnosis, drug design, and clinical management. Research over the last two decades has uncovered how acidosis alters cellular signaling, promotes genomic instability, and reprograms immune cells. The field has matured to the point where several pH-targeted therapeutic strategies are now in preclinical development and early clinical trials. This article provides an authoritative overview of the mechanisms linking pH to cancer biology, the consequences of an acidic microenvironment, and the most promising research directions for exploiting pH vulnerabilities in tumors.

The Warburg Effect: Metabolic Origins of Tumor Acidity

The hallmark of cancer cell metabolism is the Warburg effect, first described by Otto Warburg in the 1920s. Under normoxic conditions, most normal cells derive energy (ATP) primarily through mitochondrial oxidative phosphorylation, which yields 36 ATP per glucose molecule. However, cancer cells—even when ample oxygen is present—shift to aerobic glycolysis, a process that produces only 2 ATP per glucose. At first glance this seems inefficient, but the advantage lies in the rapid production of biosynthetic intermediates needed for cell growth and proliferation. The downside is a massive production of lactic acid from the conversion of pyruvate to lactate by lactate dehydrogenase (LDH).

This lactic acid is exported from the cell via monocarboxylate transporters (MCTs) such as MCT1 and MCT4, along with protons from the activity of the vacuolar ATPase (V-ATPase) and other proton pumps. The net result is a continuous acidification of the tumor’s extracellular fluid. Importantly, the intracellular pH of cancer cells remains near neutral (or even slightly alkaline) thanks to robust pH-regulating systems, creating a steep pH gradient across the plasma membrane. This gradient is exploited by many pH-sensitive processes and is itself a target for therapeutic intervention.

Recent work has expanded the Warburg paradigm by revealing that the lactate produced by glycolytic tumor cells can be taken up by adjacent oxidative tumor cells or stromal fibroblasts, a phenomenon known as the "lactate shuttle." This metabolic symbiosis further acidifies the tumor microenvironment and supports the growth of heterogeneous cell populations. Understanding these shuttling mechanisms is key to predicting how pH manipulation might affect overall tumor metabolism.

Key pH-Regulating Transporters in Cancer Cells

To survive in an acidic environment, cancer cells upregulate a suite of membrane transporters and pumps that extrude excess acid. These include:

  • Na+/H+ exchanger 1 (NHE1): Removes intracellular H+ in exchange for Na+, helping maintain a slightly alkaline pHi. NHE1 is often localized at the leading edge of migrating cancer cells, facilitating invasion.
  • Vacuolar ATPase (V-ATPase): A proton pump that moves H+ into intracellular vesicles or extracellular space; often overexpressed in invasive tumors. Isoform-specific targeting is now being explored.
  • Monocarboxylate transporters (MCT1, MCT4): Co-transport lactate and H+ out of the cell, preventing intracellular acidification. MCT4 is strongly induced by hypoxia and is a marker of poor prognosis in many cancers.
  • Carbonic anhydrases (CA9, CA12): Extracellular enzymes that catalyze the reversible hydration of CO₂, generating bicarbonate and protons, and are induced by hypoxia. CA9 is virtually absent in normal tissues but highly expressed in hypoxic tumor regions.

These transporters not only maintain pH homeostasis but also contribute to the aggressive phenotype by promoting invasion and chemoresistance. Their expression correlates with poor prognosis in multiple cancers, including breast, pancreatic, and colorectal cancer. For a comprehensive overview of pH-regulatory proteins in cancer, readers can refer to this comprehensive review on pH regulators as therapeutic targets.

How the Acidic Microenvironment Drives Cancer Progression

Promotion of Invasion and Metastasis

One of the most direct consequences of low extracellular pH is the activation of proteolytic enzymes that degrade the extracellular matrix (ECM). Acidic conditions activate matrix metalloproteinases (MMPs) and cathepsins, which cleave collagen and other ECM components, clearing a path for invading cancer cells. Furthermore, acidosis induces the expression of transcription factors such as HIF-1α (even under normoxia) and NF-κB, which drive epithelial-mesenchymal transition (EMT)—a process where stationary epithelial cells acquire migratory and invasive characteristics.

Studies have shown that exposing cancer cells to acidic medium in vitro dramatically increases their invasive capacity, and tumors with lower extracellular pH show higher rates of metastasis in animal models. The directional growth of invasive cell protrusions is also influenced by pH gradients, a phenomenon called “pH-taxis.” This suggests that not only the overall acidity but also spatial pH gradients guide cancer cells to blood vessels and lymphatic channels. Acidosis also promotes the formation of invadopodia—actin-rich protrusions that concentrate ECM-degrading enzymes at the cell-matrix interface.

Immune Evasion and Suppression

Acidosis exerts a powerful immunosuppressive effect on the tumor microenvironment. Immune effector cells, including cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and dendritic cells, require a physiological pH for optimal function. Low pH impairs T cell proliferation, cytokine production, and cytotoxic activity. It also polarizes macrophages toward an M2-like (pro-tumor) phenotype and reduces the efficacy of checkpoint inhibitors such as anti-PD-1/PD-L1 therapies.

Additionally, the acidic environment promotes the accumulation of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), both of which suppress anti-tumor immunity. These findings underscore the notion that tumor acidity is a major barrier to successful immunotherapy, and strategies to neutralize pH could enhance the effectiveness of immunotherapies. A 2020 study highlighted that buffering tumor pH restored T cell activity and improved response to PD-1 blockade in mouse models (see study details). More recently, researchers have shown that acidotic conditions can directly induce T cell exhaustion by upregulating checkpoint molecules like TIM-3 and LAG-3, further compounding immune dysfunction.

Drug Resistance Mechanisms

Chemotherapy resistance in acidic environments is multifactorial. Many conventional chemotherapeutic agents—especially weak bases like doxorubicin and mitoxantrone—become trapped in acidic compartments and are less able to reach their intracellular targets. The steep pH gradient across the membrane leads to “ion trapping,” reducing the effective drug concentration in the cytoplasm and nucleus.

Furthermore, acidosis upregulates drug efflux pumps, including P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP), and induces protective autophagy. Hypoxia and acidosis together activate the unfolded protein response (UPR) and antiapoptotic pathways, making cancer cells more resilient to treatment. This can lead to the selection of a more resistant cell population during therapy. Understanding pH-dependent drug resistance has motivated the development of pH-responsive drug delivery systems that release their payload specifically at low pH, which will be discussed later. Additionally, low pH can impair DNA repair mechanisms, paradoxically creating vulnerabilities that might be exploited with certain DNA-damaging agents when combined with pH modulation.

Promotion of Angiogenesis

Tumor acidosis profoundly influences the formation of new blood vessels. Hypoxia strongly induces the transcription factor HIF-1α, which upregulates vascular endothelial growth factor (VEGF). However, acidic pH itself can directly stimulate VEGF expression even under normoxic conditions, creating a positive feedback loop that sustains abnormal angiogenesis. The resulting tumor vasculature is often leaky and tortuous, further exacerbating heterogeneous perfusion and acidosis. This dysfunctional vasculature also impedes immune cell infiltration and drug delivery. Targeting the interplay between pH and angiogenesis is an emerging strategy: some studies suggest that normalizing tumor pH can improve vessel perfusion and reduce metastasis by limiting the hypoxic drive.

Influence on Cancer Stem Cells

Cancer stem cells (CSCs) are a subpopulation of tumor cells endowed with self-renewal capacity, tumor-initiating potential, and resistance to conventional therapy. Emerging evidence indicates that low pH helps maintain and enrich CSCs. Acidic conditions upregulate stemness-associated transcription factors such as Nanog, Oct4, and Sox2, and activate signaling pathways including Wnt/β-catenin and Notch. In breast cancer models, cells cultured at pH 6.7 exhibit a higher proportion of CD44+/CD24− (stem-like) cells and enhanced tumorigenicity. This relationship implies that pH-targeted therapies may also need to address the CSC niche to prevent recurrence.

Research Directions and Therapeutic Strategies Targeting Tumor pH

The growing recognition of the role of pH in cancer has spurred innovative therapeutic approaches aimed at either manipulating the pH environment directly or exploiting it for targeted drug delivery.

Buffer Therapy and Systemic Alkalinization

The most straightforward approach is to neutralize tumor acidity by administering buffers. Oral sodium bicarbonate has been shown to raise the intratumoral pH in mouse models and to reduce metastasis, though large-scale human trials are still lacking. Other buffers, such as lysine-based agents, TRIS (tromethamine), and imidazole derivatives, are under investigation. A major challenge is achieving sufficient buffering capacity within tumors without causing systemic alkalosis or electrolyte disturbances. Moreover, cancer cells adapt to a global increase in pH by adjusting their proton extrusion machinery, which may limit the long-term benefit of simple buffer therapy. Novel approaches use nanocarriers that localize buffer release to the tumor, potentially overcoming systemic side effects.

Inhibiting pH-Regulating Enzymes and Transporters

  • Proton pump inhibitors (PPIs): Drugs like omeprazole and esomeprazole, commonly used for gastric acid-related disorders, inhibit V-ATPase and have shown anticancer activity in preclinical models by reducing tumor acidity and sensitizing cells to chemotherapy. However, clinical results have been mixed, partly due to poor tumor penetration and off-target effects. Ongoing trials are testing high-dose PPIs in combination with chemotherapy for advanced solid tumors.
  • Carbonic anhydrase IX inhibitors: CA9 is selectively expressed under hypoxia and in many tumors (e.g., renal cell carcinoma, breast cancer). Small molecule inhibitors such as sulfonamide derivatives (e.g., SLC-0111) are being tested and have shown promise in combination with chemotherapy and immunotherapy. SLC-0111 has completed Phase I trials with acceptable safety (phase I results).
  • MCT1/MCT4 inhibitors: Blocking lactate export can cause intracellular acidification and metabolic stress in cancer cells. The MCT1 inhibitor AZD3965 has entered Phase I clinical trials for advanced solid tumors (clinical trial identifier NCT01791595). Dual targeting of MCT1 and MCT4 is being explored to overcome compensatory mechanisms.
  • NHE1 inhibitors: Pharmacological blocking of NHE1 using compounds like cariporide has been shown to reduce invasion and sensitize cells to cisplatin in preclinical models, though cardiac toxicity has limited clinical translation.

pH-Sensitive Drug Delivery Systems

Exploiting the low pH of tumors for site-specific drug release is an active area of nanomedicine. pH-sensitive liposomes, micelles, and polymeric nanoparticles are designed to remain stable at physiological pH (7.4) but rapidly release their payload at pH below 7.0. For instance, poly(β-amino ester) and acetal-based polymers are stable at neutral pH but degrade under acidic conditions, releasing chemotherapeutic agents inside the tumor. This approach can increase the therapeutic index of drugs like doxorubicin and paclitaxel while reducing systemic toxicity.

Another innovation is pH-responsive prodrugs: inactive compounds that are converted to active drugs only in an acidic milieu. Examples include the alkylating agent CBlA (which is activated at low pH) and the gemcitabine prodrug NUC-1031. Similarly, pH-low insertion peptides (pHLIPs) can target cell membranes in acidic tissues and have been used to deliver imaging agents and therapeutics to tumors. Recent advances include the development of pH-responsive nanoparticles that co-deliver multiple agents, such as a chemotherapy drug plus a checkpoint inhibitor, for combined chemoimmunotherapy.

Combination Strategies with Immunotherapy

The immunosuppressive effects of acidosis suggest that neutralizing pH could enhance checkpoint inhibitor efficacy. Early studies in syngeneic mouse models show that combining oral bicarbonate with anti-PD-1 therapy increases CD8+ T cell infiltration and reduces tumor growth. Clinical trials combining PPIs or buffers with immune checkpoint inhibitors are underway, though careful monitoring for toxicity is needed. Another strategy is to use pH-responsive nanoparticles to deliver immunostimulatory cytokines or STING agonists directly into the tumor microenvironment, thereby reducing systemic side effects. Moreover, acidotic conditions impair CAR-T cell function; preclinical work indicates that engineering CAR-T cells to maintain activity at low pH or co-administering buffers could improve their efficacy in solid tumors.

Diagnostic and Imaging Applications

Non-invasive imaging of tumor pH can help identify aggressive disease, guide treatment selection, and monitor response. Techniques such as magnetic resonance spectroscopy (MRS), chemical exchange saturation transfer (CEST) MRI, and hyperpolarized ¹³C-pyruvate imaging have been used to map intratumoral pH and lactate levels. AcidoCEST MRI, for example, can generate pH maps with spatial resolution sufficient to distinguish acidic from normal regions, potentially enabling personalized buffering or drug delivery strategies. Positron emission tomography (PET) tracers sensitive to pH, such as ¹¹C-dimethyloxazolidinedione, are also in development. A recent review discusses the state of pH imaging probes and their clinical potential (Nature Reviews Cancer article on MRI of pH).

Challenges and Future Directions

Despite significant progress, translating pH-based strategies from bench to bedside remains challenging. Tumors are heterogeneous: not all regions are uniformly acidic, and some may even be alkaline due to bicarbonate secretion from certain subgroups of cells. Additionally, systemic buffering may interfere with normal physiological processes, especially in the kidneys and gastrointestinal tract. The redundancy of pH-regulating transporters means that targeting a single protein may be compensated by others.

Future research should focus on:

  • Developing more selective inhibitors of pH-regulating enzymes with minimal off-target effects, perhaps using proteolysis-targeting chimeras (PROTACs) to degrade key transporters.
  • Imaging biomarkers to identify patients with highly acidic tumors who might benefit from pH-targeted therapies, and using dynamic pH mapping to assess treatment response.
  • Understanding the dynamic interactions between pH, immune cells, and the microbiome—gut bacteria can influence systemic acid-base balance and may modulate tumor pH indirectly.
  • Combining pH-modulating agents with emerging therapies like CAR-T cells and oncolytic viruses, both of which are sensitive to acidic conditions.
  • Investigating the role of pH in the tumor microenvironment of liquid tumors (e.g., leukemia) where the bone marrow niche may create acidic microenvironments impacting drug sensitivity.

In conclusion, the tumor microenvironment’s pH is a fundamental driver of cancer progression, drug resistance, and immune evasion. An integrated approach that combines pH manipulation with conventional and novel therapies has the potential to improve outcomes across many cancer types. Continued interdisciplinary collaboration between oncologists, biochemists, and bioengineers will be essential to realize this potential. For readers interested in a deeper dive into the molecular mechanisms linking pH to cancer hallmarks, this Nature Reviews Clinical Oncology article provides an authoritative review.